Mercury binding to the chelation therapy agents DMSA and DMPS and the rational design of custom chelators for mercury

Graham N. George, Roger C. Prince, Jürgen Gailer, Gavin A. Buttigieg, M. Bonner Denton, Hugh H. Harris, Ingrid J. Pickering

Research output: Contribution to journalArticle

81 Scopus citations

Abstract

Clinical chelation therapy of mercury poisoning generally uses one or both of two drugs-meso-dimercaptosuccinic acid (DMSA) and dimercaptopropanesulfonic acid (DMPS), commercially sold as Chemet and Dimaval, respectively. We have used a combination of mercury Lin-edge X-ray absorption spectroscopy and density functional theory calculations to investigaite the chemistry of interaction of mercuric ions with each of these chelation therapy drugs. We show that neither DMSA nor DMPS forms a true chelate complex with mercuric ions and that these drugs should be considered suboptimal for their clinical task of binding mercuric ions. We discuss the design criteria for a mercuric specific chelator molecule or "custom chelator", which might form the basis for an improved clinical treatment.

Original languageEnglish (US)
Pages (from-to)999-1006
Number of pages8
JournalChemical Research in Toxicology
Volume17
Issue number8
DOIs
StatePublished - Aug 1 2004

ASJC Scopus subject areas

  • Toxicology

Fingerprint Dive into the research topics of 'Mercury binding to the chelation therapy agents DMSA and DMPS and the rational design of custom chelators for mercury'. Together they form a unique fingerprint.

  • Cite this